Invasive Innovation for the Future
Hesaplama Aracı
Bilimsel Yayınlar
Bilimsel yayın ve çalışmalarımıza bu sayfadan ulaşabilir, bizimle iletişime geçebilirsiniz.
Fractional flow reserve and intravascular ultrasound-guided strategies for intermediate coronary stenosis and low lesion complexity in patients with or without diabetes: a post hoc analysis of the randomised FLAVOUR trial
EuroIntervention. 2025 Feb;20(11):e949-e958.
Yüksek Riskli, Kompleks Perkütan Koroner Girişimlerde Mekanik Dolaşım Desteği / MECHANICAL CIRCULATORY SUPPORT FOR COMPLEX, HIGH-RISK PERCUTANEOUS CORONARY INTERVENTION
EuroIntervention 2025;21:e149-e160
Paclitaxel- or sirolimus-coated balloons for coronary bifurcations: is the side branch SPACIOUS enough for both?
EuroIntervention. 2025;21:e290–e292 DOI: 10.4244/EIJ-E-25-00004
ANOCA/INOCA'nın Rutin Tanısı: Olumlu ve Olumsuz Yönleri Üzerine Bir Tartışma / ROUTINE DIAGNOSIS OF ANOCA/INOCA: PROS AND CONS
EuroIntervention. 2025;21:e293-e295 DOI: 10.4244/EIJ-E-24-00072
High-risk percutaneous coronary intervention in patients with reduced left ventricular ejection fraction deemed not suitable for surgical revascularisation. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) in collaboration with the ESC Working Group on Cardiovascular Surgery
EuroIntervention. 2025;21:22–34 DOI: 10.4244/EIJ-D-23-01100
Koroner Bifurkasyon Lezyonlarında Provisional Stentleme Uygulanan Hastalarda Final Kissing Balloon Dilatasyonunun Etkisi / Final kissing balloon dilatation in patients with coronary bifurcation lesions treated with an upfront provisional stenting strategy
Kaynak: ULTRA-BIFURCAT Veritabanı Analizi (BIFURCAT + ULTRA Kayıtlarının Birleştirilmesiyle)
Polymer-free amphilimus-eluting versus biodegradable-polymer everolimus-eluting stents in all-comer patients undergoing percutaneous coronary intervention: the ReCre8-AMI trial
EuroIntervention. 2025;21
Safety of coronary revascularisation deferral based on quantitative flow ratio versus fractional flow reserve: insights from the FAVOR III Europe trial
EuroIntervention. 2025;21